BIND Therapeutics to Present Data at the AACR 2014 Annual Meeting

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.

The prodrug Barasertib (AZD1152) is a potent selective inhibitor of the Aurora B kinase that successfully completed randomized Phase 2 studies in elderly AML patients unfit for chemotherapy. BIND and AstraZeneca have developed AccurinTM nanoparticle formulations of the active metabolite, AZD1152-hQPA, utilizing BIND’s medicinal nanoengineering platform to optimize critical properties for improved therapeutic index and schedule.

BIND-014 is a targeted polymeric nanoparticle containing the cytotoxic agent docetaxel (Taxotere). In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel at the site of disease which translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in two Phase 2 trials in non-small cell lung cancer and metastatic castrate resistant prostate cancer.

Details of the poster presentations at AACR:

• (Abstract #911 ): Sunday Apr 6, 2014, 1:00 p.m. - 5:00 p.m. PT, Title: “Prostate-specific membrane antigen (PSMA) expression as a potential patient selection marker in patients with refractory solid tumors administered BIND-014, a PSMA-targeted nanoparticle containing docetaxel,” Susan Low, BIND Therapeutics, Category: Clinical Research 2, Session: Predictive Biomarkers 1, Location: Hall A-E, Poster Section 37
• (Abstract # CT210 ): Monday Apr 7, 2014, 8:00 a.m. - 12:00 p.m. PT, Title: “A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, administered to patients with refractory solid tumors on a weekly schedule,” Monica Mita, Samuel Oschin Comprehensive Cancer Institute, Category: Clinical Trials 1, Session: Early Phase Clinical Trials 1: Phase I, Location: Hall A-E, Poster Section 38
• (Abstract #5409): Wednesday, April 9, 2014, 8:00 a.m. - 12:00 p.m. PT, Title: “AZD1152-hQPA Accurins: nanoparticle formulations showing extended release and the potential for improved therapeutic index,” Simon T. Barry, AstraZeneca; Jeff Hrkach, BIND Therapeutics, Category: Chemistry 11, Session: Targeted Therapies and Nanoparticle Strategies for Selective Drug Delivery, Location: Hall A-E, Poster Section 28.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer.

BIND has announced collaborations with Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.